BRIEF—Angion Biomedica and Sinovant Sciences ink deal in China

Angion Biomedica and Sinovant Sciences have entered into a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF).

Angion is currently developing BB3 in a Phase III trial for the treatment of delayed graft function (DGF) following kidney transplantation and in a Phase II trial for the treatment of acute kidney injury (AKI) following open-heart surgery requiring cardiopulmonary bypass.

Under the terms of the agreement, Angion has granted Sinovant an exclusive license to develop and commercialize the candidate in China, Hong Kong, Macau, and Taiwan. Financial details were not disclosed.